-GlcNAc Modification and Its Role in Diabetic Retinopathy.

Diabetic retinopathy (DR) is a leading complication in type 1 and type 2 diabetes and has emerged as a significant health problem. Currently, there are no effective therapeutic strategies owing to its inconspicuous early lesions and complex pathological mechanisms. Therefore, the mechanism of molecular pathogenesis requires further elucidation to identify potential targets that can aid in the prevention of DR. As a type of protein translational modification, -linked β-N-acetylglucosamine (-GlcNAc) modification is involved in many diseases, and increasing evidence suggests that dysregulated -GlcNAc modification is associated with DR. The present review discusses -GlcNAc modification and its molecular mechanisms involved in DR. -GlcNAc modification might represent a novel alternative therapeutic target for DR in the future.